CD4+CD25+FoxP3+PD1- regulatory T cells in acute and stable relapsing-remitting multiple sclerosis and their modulation by therapy
- PMID: 18587005
- DOI: 10.1096/fj.08-110650
CD4+CD25+FoxP3+PD1- regulatory T cells in acute and stable relapsing-remitting multiple sclerosis and their modulation by therapy
Abstract
The intracellular expression of the programmed death receptor 1 (PD1) identifies a subset of naive T(reg) cells with enhanced suppressive ability; antigen stimulation results in the surface expression of PD1. Because the role of T(reg) impairments in multiple sclerosis (MS) is still contradictory, we analyzed naive PD1- and PD1+ T(reg) cells in peripheral blood and cerebrospinal fluid (CSF) of relapsing-remitting multiple sclerosis (RR-MS) patients and of healthy control subjects. Results showed that 1) CSF PD1- T(reg) cells were significantly augmented in MS patients; 2) PD1- T(reg) cells were significantly increased in the peripheral blood of patients with stable disease (SMS) compared to those with acute (AMS) disease, and in patients responding to glatiramer acetate (COPA) compared to AMS- and COPA-unresponsive patients; and 3) PD1+ T(reg) cells were similar in CSF and peripheral blood of all groups analyzed. PD1- T(reg) cells were not increased in the peripheral blood of interferon-beta (IFNbeta) -responsive patients, but the suppressive ability of T(reg) cells was significantly higher in SMS and in COPA- or IFNbeta-responsive compared to AMS- and COPA-unresponsive individuals. The data herein suggest that PD1- T(reg) cells play a pivotal role in MS and offer a biological explanation for disease relapse and for the mechanism associated with response to COPA and IFNbeta.
Similar articles
-
Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study.J Neuroimmunol. 2010 Jan 25;218(1-2):120-4. doi: 10.1016/j.jneuroim.2009.10.013. Epub 2009 Nov 22. J Neuroimmunol. 2010. PMID: 19932513
-
Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression.J Neurosci Res. 2006 Jun;83(8):1432-46. doi: 10.1002/jnr.20852. J Neurosci Res. 2006. PMID: 16583400
-
Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells.Arch Neurol. 2008 Nov;65(11):1434-9. doi: 10.1001/archneur.65.11.1434. Arch Neurol. 2008. PMID: 19001161
-
CD4(+)CD25 (+) regulatory T cells in human lupus erythematosus.Arch Dermatol Res. 2009 Jan;301(1):71-81. doi: 10.1007/s00403-008-0891-9. Epub 2008 Nov 5. Arch Dermatol Res. 2009. PMID: 18985367 Review.
-
Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis.Clin Immunol. 2012 Jan;142(1):9-14. doi: 10.1016/j.clim.2011.10.008. Epub 2011 Nov 9. Clin Immunol. 2012. PMID: 22284868 Review.
Cited by
-
A narrative review of the controversy on the risk of mycobacterial infections with immune checkpoint inhibitor use: does Goldilocks have the answer?J Thorac Dis. 2024 Feb 29;16(2):1601-1624. doi: 10.21037/jtd-23-1395. Epub 2024 Feb 27. J Thorac Dis. 2024. PMID: 38505086 Free PMC article. Review.
-
Ex vivo and in vivo evidence that cigarette smoke-exposed T regulatory cells impair host immunity against Mycobacterium tuberculosis.Front Cell Infect Microbiol. 2023 Oct 26;13:1216492. doi: 10.3389/fcimb.2023.1216492. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37965256 Free PMC article.
-
Transcription Factor c-Maf Promotes Immunoregulation of Programmed Cell Death 1-Expressed CD8+ T Cells in Multiple Sclerosis.Neurol Neuroimmunol Neuroinflamm. 2022 Apr 5;9(4):e1166. doi: 10.1212/NXI.0000000000001166. Print 2022 Jul. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 35383094 Free PMC article.
-
FOXP3+ T cells in uterine sarcomas are associated with favorable prognosis, low extracellular matrix expression and reduced YAP activation.NPJ Precis Oncol. 2021 Nov 19;5(1):97. doi: 10.1038/s41698-021-00236-6. NPJ Precis Oncol. 2021. PMID: 34799669 Free PMC article.
-
Reduction of fibrosis and immune suppressive cells in ErbB2-dependent tumorigenesis by an LXR agonist.PLoS One. 2021 Mar 29;16(3):e0248996. doi: 10.1371/journal.pone.0248996. eCollection 2021. PLoS One. 2021. PMID: 33780491 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials